Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study

Cork, M.J. orcid.org/0000-0003-4428-2428, Thaçi, D., Eichenfield, L.F. et al. (12 more authors) (2020) Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study. British Journal of Dermatology. ISSN 0007-0963

Abstract

Metadata

Authors/Creators:
  • Cork, M.J. ORCID logo https://orcid.org/0000-0003-4428-2428
  • Thaçi, D.
  • Eichenfield, L.F.
  • Arkwright, P.D.
  • Sun, X.
  • Chen, Z.
  • Akinlade, B.
  • Boklage, S.
  • Guillemin, I.
  • Kosloski, M.P.
  • Kamal, M.A.
  • O’Malley, J.T.
  • Patel, N.
  • Graham, N.M.H.
  • Bansal, A.
Copyright, Publisher and Additional Information: © 2020 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
Dates:
  • Accepted: 1 August 2020
  • Published (online): 24 September 2020
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 13 Oct 2020 12:03
Last Modified: 13 Oct 2020 12:03
Status: Published online
Publisher: Wiley
Refereed: Yes
Identification Number: https://doi.org/10.1111/bjd.19460
Related URLs:

Download

Filename: bjd.19460.pdf

Licence: CC-BY-NC-ND 4.0

Share / Export

Statistics